A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder

• Published in: Journal of psychiatric research Vol. 45; no. 6; pp. 748 - 755
• Main Authors: Pangallo, Beth, Dellva, Mary Anne, D’Souza, Deborah N., Essink, Beal, Russell, James, Goldberger, Celine
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 01.06.2011; Elsevier
• Subjects: Adolescent; Adrenergic Uptake Inhibitors - administration & dosage; Adrenergic Uptake Inhibitors - adverse effects; Adult; Adult and adolescent clinical studies; Aged; Antidepressive Agents - administration & dosage; Antidepressive Agents - adverse effects; Biological and medical sciences; Depression; Depressive Disorder, Major - drug therapy; Depressive personality disorders; Diagnostic and Statistical Manual of Mental Disorders; Disability; Discontinued; Dose-Response Relationship, Drug; Double-Blind Method; Efficacy; Female; Humans; LY2216684; Major depressive disorder; Male; Medical sciences; Middle Aged; Mood disorders; Morpholines - administration & dosage; Morpholines - adverse effects; Norepinephrine; Phenylethyl Alcohol - administration & dosage; Phenylethyl Alcohol - adverse effects; Phenylethyl Alcohol - analogs & derivatives; Psychiatric Status Rating Scales; Psychiatry; Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Remission; Safety; Treatment Outcome; Young Adult; Efficacy; Norepinephrine; Safety; Major depressive disorder; LY2216684; Mood disorder; Treatment; Placebo; Neurotransmitter; Double blind study; Depression; Catecholamine

The efficacy, tolerability, and safety of LY2216684, a highly selective norepinephrine reuptake inhibitor, were studied in adult patients with major depressive disorder (MDD). This randomized, double-blind study compared flexible-dose LY2216684 6–18 mg once daily (N = 250) with placebo (N = 245) for...